REGENXBIO (RGNX) Revenue & Revenue Breakdown
REGENXBIO Revenue Highlights
Latest Revenue (Y)
$90.24M
Latest Revenue (Q)
$22.30M
Main Segment (Y)
License and Service
REGENXBIO Revenue by Period
REGENXBIO Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $90.24M | -19.94% |
| 2022-12-31 | $112.72M | -76.03% |
| 2021-12-31 | $470.35M | 204.30% |
| 2020-12-31 | $154.57M | 338.70% |
| 2019-12-31 | $35.23M | -83.88% |
| 2018-12-31 | $218.50M | 2002.42% |
| 2017-12-31 | $10.39M | 126.48% |
| 2016-12-31 | $4.59M | -39.52% |
| 2015-12-31 | $7.59M | 23.99% |
| 2014-12-31 | $6.12M | 0.54% |
| 2013-12-31 | $6.09M | - |
REGENXBIO generated $90.24M in revenue during NA 2023, up -19.94% compared to the previous quarter, and up 41.30% compared to the same period a year ago.
REGENXBIO Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $22.30M | 42.72% |
| 2024-03-31 | $15.62M | -29.67% |
| 2023-12-31 | $22.21M | -23.18% |
| 2023-09-30 | $28.91M | 44.74% |
| 2023-06-30 | $19.98M | 4.38% |
| 2023-03-31 | $19.14M | -38.94% |
| 2022-12-31 | $31.34M | 18.23% |
| 2022-09-30 | $26.51M | -18.80% |
| 2022-06-30 | $32.65M | 46.95% |
| 2022-03-31 | $22.22M | -94.43% |
| 2021-12-31 | $398.65M | 1195.47% |
| 2021-09-30 | $30.77M | 39.66% |
| 2021-06-30 | $22.04M | 16.69% |
| 2021-03-31 | $18.88M | -11.94% |
| 2020-12-31 | $21.45M | -78.32% |
| 2020-09-30 | $98.91M | 497.08% |
| 2020-06-30 | $16.57M | -6.11% |
| 2020-03-31 | $17.64M | 49.93% |
| 2019-12-31 | $11.77M | -19.95% |
| 2019-09-30 | $14.70M | 86.52% |
| 2019-06-30 | $7.88M | 791.52% |
| 2019-03-31 | $884.00K | -97.83% |
| 2018-12-31 | $40.78M | 668.51% |
| 2018-09-30 | $5.31M | -86.75% |
| 2018-06-30 | $40.03M | -69.76% |
| 2018-03-31 | $132.39M | 6389.75% |
| 2017-12-31 | $2.04M | 52.69% |
| 2017-09-30 | $1.34M | -79.64% |
| 2017-06-30 | $6.56M | 1342.20% |
| 2017-03-31 | $455.00K | -73.17% |
| 2016-12-31 | $1.70M | 1256.80% |
| 2016-09-30 | $125.00K | -94.74% |
| 2016-06-30 | $2.38M | 504.33% |
| 2016-03-31 | $393.00K | -91.16% |
| 2015-12-31 | $4.45M | 290.18% |
| 2015-09-30 | $1.14M | -16.36% |
| 2015-06-30 | $1.36M | 111.65% |
| 2015-03-31 | $644.00K | -43.90% |
| 2014-12-31 | $1.15M | 137.68% |
| 2014-09-30 | $483.00K | - |
REGENXBIO generated $22.30M in revenue during Q2 2024, up 42.72% compared to the previous quarter, and up 116.50% compared to the same period a year ago.
REGENXBIO Revenue Breakdown
REGENXBIO Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License and Service | $90.24M | $112.72M | - | - | - |
| License And Service | - | - | $470.35M | $154.57M | - |
| License | - | - | - | - | $3.50M |
| Zolgensma Royalties | - | - | - | - | $20.83M |
REGENXBIO's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Service | $22.30M | $15.62M | $70.27M | $19.98M | $31.34M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License And Service | - | - | - | - | $19.14M | $26.51M | $32.65M | $22.22M | $398.65M | $30.77M | $22.04M | $18.88M | - | - | - | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.50M | $3.50M | - | - |
| Zolgensma Royalties | - | - | - | - | - | - | - | - | - | - | - | - | - | $20.91M | $18.80M | $11.95M | $9.98M | $10.72M | - |
| Achievement Of Sales Based Milestone For Zolgensma | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $80.00M | - | - | - | - |
REGENXBIO's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: License and Service (100.00%).
REGENXBIO Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IMCR | Immunocore | $249.43M | $75.40M |
| MIRM | Mirum Pharmaceuticals | $186.37M | $69.22M |
| RGNX | REGENXBIO | $90.24M | $22.30M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| QURE | uniQure | $15.84M | $11.13M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| KZR | Kezar Life Sciences | $7.00M | - |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| LIAN | LianBio | - | - |
| ANTX | AN2 Therapeutics | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| REPL | Replimune Group | - | - |
| RCKT | Rocket Pharmaceuticals | - | - |
| PASG | Passage Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| FDMT | 4D Molecular Therapeutics | - | - |
RGNX Revenue FAQ
What is REGENXBIO’s yearly revenue?
REGENXBIO's yearly revenue for 2023 was $90.24M, representing a decrease of -19.94% compared to 2022. The company's yearly revenue for 2022 was $112.72M, representing a decrease of -76.03% compared to 2021. RGNX's yearly revenue for 2021 was $470.35M, representing an increase of 204.30% compared to 2020.
What is REGENXBIO’s quarterly revenue?
REGENXBIO's quarterly revenue for Q2 2024 was $22.3M, a 42.72% increase from the previous quarter (Q1 2024), and a 11.60% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $15.62M, a -29.67% decrease from the previous quarter (Q4 2023), and a -18.37% decrease year-over-year (Q1 2023). RGNX's quarterly revenue for Q4 2023 was $22.21M, a -23.18% decrease from the previous quarter (Q3 2023), and a -29.13% decrease year-over-year (Q4 2022).
What is REGENXBIO’s revenue growth rate?
REGENXBIO's revenue growth rate for the last 3 years (2021-2023) was -80.81%, and for the last 5 years (2019-2023) was 156.13%.
What are REGENXBIO’s revenue streams?
REGENXBIO's revenue streams in c 23 are License and Service
What is REGENXBIO’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of REGENXBIO was License and Service. This segment made a revenue of $90.24M, representing 100.00% of the company's total revenue.